HMG-CoA Reductase Inhibitors in Chronic Heart Failure: Potential Mechanisms of Benefit and Risk

By Laufs Ulrich   Custodis Florian   Böhm Michael  

Drugs, Vol. 66, Iss. 2, 2006-01 ,pp. : 145-154

Adis International

Access to resources Recommend Favorite

Depression in chronic heart failure: novel pathophysiological mechanisms and therapeutic approaches

By Parissis John T   Fountoulaki Katerina   Paraskevaidis Ioannis   Kremastinos Dimitrios  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 5, 2005-05 ,pp. : 567-577

Informa Healthcare

Access to resources Recommend Favorite

Mechanisms Explaining the Influence of Subclinical Hypothyroidism on the Onset and Progression of Chronic Heart Failure

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 16, Iss. 1, 2016-03 ,pp. : 2-7

Bentham Science Publishers

Access to resources Recommend Favorite

Vasopressin Receptor Antagonists: Therapeutic Potential in the Management of Acute and Chronic Heart Failure

By Russell S.D.   DeWald T.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 1, 2003-01 ,pp. : 13-20

Adis International

Access to resources Recommend Favorite

Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches

By  

Current Pharmaceutical Design, Vol. 22, Iss. 31, 2016-09 ,pp. : 4807-4822

Bentham Science Publishers

Access to resources Recommend Favorite